描述
Overview of clinical trial design considerations for testing mitochondria-targeted interventions in neurodegenerative disease populations, including patient selection criteria and biomarker endpoints.
Figure 26
Source Paper
Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence.Cite This Figure
![Figure 26: Overview of clinical trial design considerations for testing mitochondria-targeted interventions in neurodegenerative disease populations, including patient selection criteria and biomarker endpoints.]() > Source: Imane Lejri et al. "Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Rel." *Oxidative medicine and cellular longevity*, 2019. PMID: [31214285](https://pubmed.ncbi.nlm.nih.gov/31214285/)
<figure> <img src="" alt="Overview of clinical trial design considerations for testing mitochondria-targeted interventions in neurodegenerative disease populations, including patient selection criteria and biomarker endpoints." /> <figcaption>Figure 26. Overview of clinical trial design considerations for testing mitochondria-targeted interventions in neurodegenerative disease populations, including patient selection criteria and biomarker endpoints.<br> Source: Imane Lejri et al. "Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Rel." <em>Oxidative medicine and cellular longevity</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31214285/">31214285</a></figcaption> </figure>